Autonomous Treatment of Bacterial Infections in Vivo Using Antimicrobial Micro- and Nanomotors

Xavier Arqué, Marcelo D. T. Torres, Tania Patiño, Andreia Boaro, Samuel Sánchez, César de la Fuente‐NúñezACS 2022 · DOI

Abstract

The increasing resistance of bacteria to existing antibiotics constitutes a major public health threat globally. Most current antibiotic treatments are hindered by poor delivery to the infection site, leading to undesired off-target effects and drug resistance development and spread. Here, we describe micro- and nanomachines that effectively and autonomously deliver antibiotic payloads to the target area. The active motion and antimicrobial activity of the silica-based robots are driven by catalysis of the enzyme urease and antimicrobial peptides, respectively. These antimicrobial machines show micromolar bactericidal activity in vitro against different Gram-positive and Gram-negative pathogenic bacterial strains and act by rapidly depolarizing their membrane. Finally, they demonstrated autonomous anti-infective efficacy in vivo in a clinically relevant abscess infection mouse model. In summary, our machines combine navigation, catalytic conversion, and bactericidal capacity to deliver antimicrobial payloads to specific infection sites. This technology represents a much-needed tool to direct therapeutics to their target to help combat drug-resistant infections.

Introduction

We are currently facing a "silent pandemic" of antibiotic resistance. While much research focuses on discovering new chemical compounds, a significant bottleneck remains: delivery. Most antibiotics are administered systemically or topically as passive molecules that rely on simple diffusion to reach the heart of an infection. This often results in sub-lethal doses at the target site—which encourages further resistance—and high systemic concentrations that cause off-target effects by killing healthy microbiota.

To address this, researchers have developed a class of "bioactive machines" designed to actively navigate toward and penetrate infection sites. By transitioning from passive diffusion to active, autonomous propulsion, these micro- and nanomachines can overcome the physical barriers of complex biological environments, such as abscesses and deep wounds.

Design and Methodology

The study utilized two distinct silica-based architectures to create these autonomous hunters:

  1. Hollow Silica Microparticles (HSMP): Spheres approximately 1.87 μm in diameter.
  2. Mesoporous Silica Nanoparticles (MSNP): Smaller particles approximately 694 nm in diameter.

The Propulsion System

Both particle types were functionalized with the enzyme urease. This enzyme serves as the machine's "engine" by catalyzing the hydrolysis of urea—a common metabolite found throughout the human body. This chemical reaction creates a local gradient that propels the particle forward, allowing for self-propulsion without the need for external magnetic or electric fields.

The Antimicrobial Payload

The machines were coated with Antimicrobial Peptides (AMPs), specifically the natural peptide LL-37 and the synthetic peptide K7-Pol. Unlike traditional antibiotics that target specific metabolic pathways, these peptides kill bacteria by physically disrupting and depolarizing their membranes, a mechanism that is much harder for bacteria to evolve resistance against.

Experimental Results

In Vitro Performance against ESKAPE Pathogens

The machines were tested against a panel of high-priority human pathogens, known as the ESKAPE list, including Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus. The machines demonstrated broad-spectrum activity with Minimum Inhibitory Concentrations (MICs) as low as 7.8 μg/mL. Fluorescence assays confirmed that the machines kill by rapidly depolarizing the bacterial membrane upon contact.

Autonomous Navigation and Speed

In the presence of urea fuel, the micromachines achieved speeds between 3.3 and 4.3 μm/s. Interestingly, the researchers found that the attachment of positively charged peptides actually enhanced propulsion. The increased surface charge (zeta potential) likely improved conductivity, thereby strengthening the electric fields that drive the machines' motion in ionic environments.

In Vivo Efficacy in Abscess Models

The most critical test occurred in a clinically relevant mouse skin abscess model. When passive peptides (free LL-37 or K7-Pol) were injected into one side of a 1 cm wound, they remained localized, failing to clear the infection on the opposite side. In contrast, the enzyme-powered nanomachines utilized the urea present in the tissue to swim across the entire wound area. This active navigation resulted in a bacterial load reduction of 2 to 3 orders of magnitude (99% to 99.9%) compared to untreated controls.

Discussion and Future Outlook

This research demonstrates that active transport is fundamentally superior to passive diffusion for treating localized infections. The ability of these machines to "hunt" bacteria across a tissue environment represents a significant leap in drug delivery technology.

However, several factors must be addressed before clinical translation:

  • Environmental Complexity: The ionic strength of living tissue can dampen the catalytic engine, requiring precise calibration of the machine's surface charge to maintain speed in vivo.
  • Fuel Dynamics: While urea is ubiquitous, its concentration varies by tissue type (e.g., higher in the urinary tract than the skin), which may dictate where these machines are most effective.
  • Biocompatibility: While no acute toxicity or distress was observed in the 4-day mouse trials, future studies must investigate the long-term clearance of silica particles from the body.

By combining navigation, catalytic conversion, and potent bactericidal capacity, these antimicrobial machines provide a robust framework for the next generation of "intelligent" therapeutics in the fight against multi-drug resistant infections.

Summary updated

Abstract

The increasing resistance of bacteria to existing antibiotics constitutes a major public health threat globally. Most current antibiotic treatments are hindered by poor delivery to the infection site, leading to undesired off-target effects and drug resistance development and spread. Here, we describe micro- and nanomotors that effectively and autonomously deliver antibiotic payloads to the target area. The active motion and antimicrobial activity of the silica-based robots are driven by catalysis of the enzyme urease and antimicrobial peptides, respectively. These antimicrobial motors show micromolar bactericidal activity <i>in vitro</i> against different Gram-positive and Gram-negative pathogenic bacterial strains and act by rapidly depolarizing their membrane. Finally, they demonstrated autonomous anti-infective efficacy <i>in vivo</i> in a clinically relevant abscess infection mouse model. In summary, our motors combine navigation, catalytic conversion, and bactericidal capacity to deliver antimicrobial payloads to specific infection sites. This technology represents a much-needed tool to direct therapeutics to their target to help combat drug-resistant infections.
BibTeX
@inproceedings{arque2022autonomous,
  author = {Xavier Arqué and Marcelo D. T. Torres and Tania Patiño and Andreia Boaro and Samuel Sánchez and César de la Fuente‐Núñez},
  title = {{Autonomous Treatment of Bacterial Infections <i>in Vivo</i> Using Antimicrobial Micro- and Nanomotors}},
  booktitle = {ACS},
  year = {2022},
  doi = {10.1021/acsnano.1c11013},
}

Loading related content...

Figure